A landmark study published in Science Advances has uncovered how epithelial ovarian cancer cells recruit the abdominal cavity’s own mesothelial cells to form hybrid tumour clusters that invade tissue with alarming efficiency, resist chemotherapy, and metastasise at a pace that has long baffled clinicians. The findings explain a mechanism central to the disease’s notoriously
poor prognosis and point towards new therapeutic targets.
Ovarian cancer kills more women than any other gynaecological malignancy, and the reason for its devastating speed has never been fully understood – until now. A new study from Nagoya University, published on 6 February 2026 in Science Advances, reveals that epithelial ovarian cancer (EOC) cells do not spread alone. Instead, they conscript the mesothelial cells that line the abdominal cavity, forming hybrid spheroids that act as highly efficient invasion machines.
The research, led by Dr Kaname Uno and Professor Masato Yoshihara at Nagoya University’s Graduate School of Medicine, draws on clinical ascites samples from 1,856 patients with ovarian cancer, advanced multiphoton microscopy, sin-gle-cell RNA sequencing (scRNA-seq), mouse models, and proteomic analysis to construct a detailed mechanistic picture of peritoneal metastasis – the process by which cancer disseminates across the abdominal cavity.
Cancer spheroids – not single cells – dominate the ascites
One of the study’s most striking early findings concerns the physical form of cancer cells in ascitic fluid. Previous models frequently described EOC cells as travelling through the abdominal cavity as single entities. The Nagoya team found this to be the exception rather than the rule. Examining cytology slides from clinical ascites specimens, they found that 99.5% of EOC cells were present as spheroids – compact, multicellular clusters. Furthermore, morphological assessment, immunohistochemical staining, and scRNA-seq analysis consistently identified mesothelial cells as the predominant non-malignant cell type in ascites, accounting for approximately 30% of its cellular composition.
Using the marker HBME1 – identified as the most reliable tool for distinguishing mesothelial from cancer cells – the investigators examined 383 EOC spheroids from 28 patients with high-grade serous ovarian carcinoma (HGSOC). More than 60% contained mesothelial cells. Strikingly, in patients who had received chemotherapy prior to surgery, the proportion of HBME1-positive mesothelial cells within spheroids was significantly higher than in treatment-naïve patients (29.8% versus 13.8%, P < 0.001), suggesting that mesothelial-enriched clusters confer chemotherapy resistance.
ACMSs: A partnership that weaponises normal cells
The researchers termed these hybrid structures aggregated cancer-mesothelial spheroids (ACMSs). Their key discovery was that when EOC cells form spheroids with mesothelial cells, it is the mesothelial cells – not the cancer cells – that lead the invasion. Using real-time time-lapse imaging and collagen invasion assays, they observed a clear four-phase sequence: the initial mixing of cell types within the ACMS; attachment to the mesothelial layer; aggressive invasion by mesothelial cells; and finally the migration of EOC cells through the pathways created.
In quantitative terms, the invasive area of ACMSs extended to more than 400% of the original spheroid area within 48 hours, compared with just 125% for spheroids composed solely of EOC cells. Mesothelial cells from ACMSs invaded collagen to a depth exceeding 300 µm, while homotypic EOC spheroids penetrated less than 100 µm. As the authors note, “EOC cells alter mesothelial cell characteristics through spheroid formation to acquire invasion capabilities into the mesothelial layer.”
The TGF-β1 signal: cancer as puppet master
To understand why mesothelial cells become so aggressive within ACMSs, the team performed RNA sequencing on both cell types before and after spheroid formation. The results were striking in their asymmetry. RNA expression changes in EOC cells were relatively minor – only 70 genes were up-regulated – whilst mesothelial cells showed profound transcriptional reprogramming, with 455 genes up-regulated. The authors conclude that “EOC cells can induce peritoneal metastasis without direct dynamic RNA expression changes.”
The principal driver of mesothelial cell transformation was identified as transforming growth factor- β1 (TGF-β1), secreted in high concentrations by EOC cells. TGF-β1 stimulation activated the Notch, PI3K-Akt, MAPK, and TGF-β pathways in mesothelial cells and up-regulated genes associated with epithelial-to-mesenchymal transition. This molecular reprogramming induced the formation of invadopodia – actin-based spike-like protrusions essential for degrading the extracellular matrix (ECM). TGF-β1-stimulated mesothelial cells developed more than 30 invadopodia per cell, compared with approximately 5 in unstimulated cells.
The key molecular effector downstream of TGF-β1 was identified as fascin-1, encoded by FSCN1, an actin-bundling protein critical to invadopodium maturation. Western blotting confirmed up-regulation of fascin-1, Tks5, integrin β1, and myosin X in TGF-β1-stimulated mesothelial cells. Matrix metalloproteinase MMP14, which activates MMP2 to degrade collagen, was also elevated and localised at invadopodia. When EOC cells were treated with siRNA targeting TGF-β1, or when mesothelial cells were pre-treated with a TGF-β1 receptor blocker, the invasive capacity of ACMSs was significantly curtailed in both in vitro and in vivo models.
Fascin-1: A prognostic marker and treatment target
Fascin-1 expression in stromal cells – predominantly mesothelial cells at metastatic sites – was significantly associated with worse progression-free survival in patients with HGSOC (P = 0.030, hazard ratio 2.15). By contrast, fascin-1 expression in cancer cells themselves showed no such prognostic correlation (P = 0.739). The fascin inhibitor NP-G2-044, currently in phase 2 clinical trials with a focus on ovarian cancer, significantly reduced collagen degradation by TGF-β1-stimulated mesothelial cells in vitro, suggesting a plausible therapeutic avenue.
A personal motivation behind the research
The study was in part driven by a clinician’s direct experience of the disease’s ferocity. Dr Uno, who practised as a gynaecologist for eight years before pursuing research, described the case that redirected his career: “She had clear screening results just three months before doctors found advanced ovarian cancer. Current medical tools failed to detect the cancer early enough to save her life.” That experience motivated him to investigate why ovarian cancer spreads so rapidly.
The clinical data underpinning this work are substantial. Among 983 patients with HGSOC or endometrioid carcinoma drawn from the Tokai Ovarian Cancer Group, positive cytology – indicating the presence of EOC cells in ascitic fluid – was independently associated with significantly shorter progression-free survival at all disease stages (hazard ratio 1.430; 95% CI: 1.157–1.766, multivariate analysis).
Reframing the tumour microenvironment in ascites
The study also corrects an important analytical blind spot in earlier scRNAseq datasets. Several published analyses had failed to identify mesothelial cells as a distinct population in ascites, instead misclassifying them as fibroblasts. The Nagoya team re-analysed three separate datasets and confirmed that cells previously annotated as fibroblasts in ascites samples robustly expressed mesothelialspecific markers including LRRN4, KRT8, KRT18, MSLN, UPK3B, and WT1. More than 90% of stromal cells in ascites were, in fact, mesothelial cells.
Because ACMSs are detectable in ascitic fluid, monitoring the composition of these clusters could also offer a noninvasive means of tracking disease progression and predicting chemotherapy response. In their conclusion, the authors are direct: “These findings represent a unique characteristic of ovarian cancer in that it rapidly induces numerous peritoneal metastases within a few months of acquiring malignant characteristics… This indicates that targeting ACMSs may be a suitable treatment strategy to reduce EOC cell survival in ascites, invasion of the peritoneal cavity, and resistance to chemotherapy.”
By demonstrating that ovarian cancer effectively outsources its most destructive work to co-opted normal cells – leaving its own genome relatively unchanged – this study reframes how researchers and clinicians must think about EOC progression. The cancer’s apparent lack of aggressive genetic evolution is not a limitation; it is a strategy. Blocking the TGF-ß1/fascin-1 axis, or disrupting ACMS formation itself, may represent the most rational approach yet to slowing one of gynaecological oncology’s most lethal diseases.
Reference:
Uno, K., Yoshihara, M., Yamakita, Y., et al. (2026). Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation. Science Advances, 12, eadu5944. https://doi.org/10.1126/sciadv.adu5944
